Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Rare Disease Day 2020: Orphan drugs face uphill battle in 2020

As patients, clinicians and researchers prepare for Rare Disease Day on February 29 2020, GlobalData’s analysis shows the number of drugs awarded orphan drug designations (ODDs) by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has declined over the last six years, despite the benefits of these designations in speeding […]
Read more

Agile Therapeutics’ Twirla could carve out meaningful share in US contraceptive market

Agile Therapeutics’ Twirla (ethinyl estradiol + levonorgestrel) could have an edge over competitors based on milder side-effects and a potentially safer profile, says GlobalData, a leading data and analytics company. As the largest contraceptives market, the US will experience moderate growth at a compound annual growth rate (CAGR) of 4.8%, reaching $5.2bn total sales by 2027. This market offers several options, including both on-demand and longer-acting approaches, and has […]
Read more

Latest drug approved for migraine prevention will struggle to compete in a crowded market space

Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and Teva’s Ajovy all of which were approved in the past two years. “In order to stand out in this crowded market Lundbeck are drawing attention to the improved dosing schedule of every 12 weeks for Vyepti, which they hope will give it a competitive advantage over the other available drugs which require dosing every four […]
Read more

Promising pipeline products anticipated to bolster treatment options for dry eye syndrome

Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see a significant change in the next ten years thanks to a number of promising therapies currently in pipeline development.    According to GlobalData, there are 52 pipeline products in different stages of development, which include Phase I, II and III products across the nine […]
Read more

Dr Reddy’s takes inorganic route to grow in India, says GlobalData

Following the recent news that Dr Reddy’s Laboratories (DRL) has agreed to acquire Wockhardt Ltd’s select divisions of branded generics business in India, Nepal, Sri Lanka, Bhutan and Maldives for a consideration of INR18.5bn (US$260m); Prashant Khadayate, Practice Head of Healthcare at GlobalData, a leading data and analytics company, offers his view: “Dr Reddy’s has […]
Read more

US dermatophytic onychomycosis market set to reach $676.4m by 2028

The dermatophytic onychomycosis market is expected to grow from $208.8m in 2018 to $676.4m in 2028 within the US, at a compound annual growth rate (CAGR) of 12.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028’, states that the US dermatophytic […]
Read more

Government direct intervention set to enhance quality and safety of drugs in India, says GlobalData

Following the recent official gazette notification from the Ministry of Health & Family Welfare (MOHFW) of India that from March 2021 onwards Indian pharmaceutical companies that market drugs will be accountable for quality and other regulatory compliances along with the manufacturers; Anupama, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: […]
Read more

Pfizer’s Vyndaqel set to achieve blockbuster status in 2021 with new EU approval for expanded use in ATTR-CM

Following today’s news that Pfizer’s rare disease oral drug Vyndaqel (tafamidis) has gained a new European Medicines Agency (EMA) approval for treating adults with wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM); Sarah Elsayed, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “This new approval will dramatically increase the patient pool […]
Read more

Zydus and CMS partnership provides momentous boost to commercialization strategy for desidustat in China, says GlobalData

India-based Zydus Cadila’s licensing agreement with China Medical System (CMS) Holdings Limited in January 2020 for the development and commercialization of desidustat will provide a momentous boost to the overall commercialization strategy for the anemia drug, says GlobalData, a leading data and analytics company. Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is indicated […]
Read more

SCTM roadmap and committed funding will boost Australia’s position in Asia-Pacific stem cell research landscape, says GlobalData

The recently published final roadmap for Stem Cell Therapies Mission (SCTM), grant opportunities and stem cell research regulations will further streamline an already agile stem cell research sector and boost Australia’s position in the Asia-Pacific stem cell research landscape, says GlobalData, a leading data and analytics company. GlobalData’s report, ‘CountryFocus: Healthcare, Regulatory and Reimbursement Landscape […]
Read more

Oncology dominates clinical trials activity in 2020, says GlobalData

Oncology is set to dominate the clinical trials activity in 2020 based on an early preview of trials that are expected to start and be completed in the year, according to GlobalData, a leading data and analytics company.  In addition, industry-sponsored trials are expected to dominate the planned clinical trial landscape in 2020, accounting for […]
Read more

Vildagliptin’s affordability will provide competitive advantage to Eris and Cipla in crowded Indian diabetes market, says GlobalData

Novartis has recently sold its anti-diabetic drug vildagliptin (branded as Zomelis, Vysov and Vysov M) to Ahmedabad-based Eris Lifesciences and Mumbai-based pharmaceutical major Cipla Ltd, in India. The orally active, potent and selective dipeptidyl peptidase -4 (DPP-4) inhibitor’s patent has expired in India leading to increased affordability of vildagliptin. Product acquisition and increased affordability of […]
Read more

Another blow for Alzheimer’s disease patients as Lilly and Roche’s drugs fail to slow cognitive decline

Following the failure of a trial for two monoclonal antibody drugs for Alzheimer’s disease (AD), Eli Lilly’s solanezumab and Roche’s gantenerumab, in patients that have a rare genetic mutation that causes early-onset AD; Alessio Brunello, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “The data from the trial DIAN-TU […]
Read more

AI finally making its mark in pharma as first AI-generated drug enters clinical trials, says GlobalData

In 2020, big data and artificial intelligence (AI) will continue to trend as integral parts of the future of pharmaceutical research and healthcare service delivery, says GlobalData, a leading data and analytics company. The company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2020’, reveals that 65% of pharma managers and executives […]
Read more

Growing HealthTech market in Malaysia offers myriad opportunities for domestic and foreign firms, says GlobalData

Malaysia’s aspiration to push HealthTech to the forefront will provide myriad opportunities to innovative domestic and foreign companies, according to GlobalData, a leading data and analytics company. Through supportive government policies and investment initiatives, Malaysia offers conducive business environment to the HealthTech sector. However, shortage of skilled staff, advanced equipment and facilities are some of […]
Read more
1 … 100 101 102 103 104 … 108